A new family of peptide receptors, the incretin receptor family, overexpressed on many neuroendocrine tumors (NETs) is of great importance because it may enable the in vivo peptide-based receptor targeting of a category of NETs that does not express the somatostatin receptor. Impressive in vivo diagnostic data were published for glucagonlike peptide 1 receptor-targeting radiopeptides. Recently, promising in vitro data have appeared for the second member of the incretin family, the glucose-dependent insulinotropic polypeptide (GIP) receptor. This prompted us to develop and evaluate a new class of radioligands with the potential to be used for the in vivo targeting of GIP receptor-positive tumors. Methods: GIP(1-42) was modified C-terminally, and the truncated peptides showed high affinity toward GIP receptor for the GIP conjugates. Specific in vitro internalization was found, and almost the entire cellassociated activity was internalized (.90% of the cell-bound activity), supporting the agonist potency of the 111 In-EG4 and 68 Ga-EG4 were shown to specifically target INR1G9-hGIPr xenografts, with tumor uptake of 10.4% ± 2.2% and 17.0% ± 4.4% injected activity/g, 1 h after injection, respectively. Kidneys showed the highest uptake, which could be reduced by approximately 40%-50% with a modified-fluid-gelatin plasma substitute or an inhibitor of the serine protease dipeptidyl peptidase 4. The PET images clearly visualized the tumor. Conclusion: The evaluation of EG4 as a proof-ofprinciple radioligand indicated the feasibility of imaging GIP receptorpositive tumors. These results prompt us to continue the development of this family of radioligands for imaging of a broad spectrum of NETs.
Ther egulatory peptides and their receptors have gained an important role in the targeted imaging and radionuclide therapy of cancer over the last few decades. Overexpression of the receptors on the surface of cancer cells, in combination with their considerably low expression in surrounding healthy tissues, is the key to successful application of these methods in the field of nuclear medicine (1, 2) .
The somatostatin receptor was the first to be defined for in vivo targeting. The overexpression of somatostatin receptor on neuroendocrine tumors (NETs) has allowed tumor localization, staging, therapy follow-up, and targeted radionuclide therapy (3) . Radiolabeled somatostatin analogs can be used to localize NETs with high specificity and sensitivity, translating into successful targeted radionuclide therapy or to PET imaging (4) (5) (6) (7) . Although the overexpression of somatostatin has proven to be an important tool for the targeting of NETs, there are limitations since not all NETs express somatostatin (8) . Therefore, the identification of other families of receptors that would enable the in vivo targeting of those tumors is of high importance (9) . A new and promising family of G-proteincoupled receptors is the incretin receptor family (8, 10, 11) . The imaging of tumors overexpressing the glucagonlike peptide 1 (GLP-1) receptor was proven to be successful in insulinoma preclinically (12) (13) (14) (15) (16) (17) and clinically (18, 19) . Recently, it was found that the second member of the incretin receptor family, the glucose-dependent insulinotropic polypeptide (GIP) receptor, is overexpressed in specific NETs. Most somatostatin-negative NETs (;90%) and GLP-1 receptor-negative malignant insulinomas are GIP receptor-positive (20) .
GIP is a 42-amino-acid polypeptide synthesized by K cells of the duodenum and small intestine. Like its sister incretin hormone GLP-1, GIP is secreted by the intestine, causing a glucose-dependent release of insulin from the b cells and inhibition of glucagon from the a cells (21, 22) . GIP is rapidly inactivated to GIP by the widespread serine protease dipeptidyl peptidase (DPP) 4, with a plasma half-life of approximately 5-7 min (23, 24) . The intact N-terminal and parts of the first 30 amino acids are necessary for biologic activity and binding to the GIP receptor-binding pocket with high affinity (25) (26) (27) . GIP receptor belongs to the subfamily B1 of the G protein-coupled receptor superfamily, specifically the glucagon receptor family, and is expressed in low density throughout the human body (22, 25) . In pathologic conditions, GIP receptor is overexpressed in functional (such as insulinomas and gastrinomas) and nonfunctional pancreatic, ileal, and bronchial NETs. Malignant insulinomas are an interesting case of cancer since they all seem to preserve GIP receptor expression while seldom expressing somatostatin and GLP-1 receptors. The high expression of GIP receptor in these cases of NETs, in contrast to the low physiologic expression as proven by autoradiographic studies and messenger RNA analysis, may lead to high tumor-to-background ratios and fulfill the prerequisite for successful in vivo peptide receptor targeting (20) .
In this study, we developed and evaluated a new class of GIPbased radioligands with the potential to image a broad spectrum of NETs. Three GIP-based radioligands, [Lys 30 
MATERIALS AND METHODS
The supplier information for all reagents and details of instruments used are provided in the supplemental data (supplemental materials are available at http://jnm.snmjournals.org).
Radiolabeling with 111 In and 68 Ga
The radioligands were prepared as described in detail in the supplemental data. Briefly, 111 In-conjugates were prepared by dissolving 20 mg (5 nmol) of peptide in 250 mL of ammonium acetate buffer (0.5 mol/L, pH 5.4), followed by incubation with 111 InCl 3 (35-40 MBq) for 30 min at 95°C. After the labeling with 111 In, one equivalent of nat InCl 3 · 2H 2 O was added and the final solution was incubated again at 95°C for 30 min to obtain structurally characterized homogeneous ligands, which were used for the saturation binding studies. 68 Ga-conjugates were prepared within 10 min at 95°C starting with 40 mg of the conjugates, followed by purification using the Modular-Lab PharmTracer module (Eckert and Ziegler).
Cell Line
Hamster glucagon-secreting pancreatic cells (INR1G9) kindly given by Prof. Jacques Philippe, University of Geneva, Switzerland, were transfected with pcDNA3 vector containing human cDNA encoding short variant of the human GIP receptor using lipofectamine. Selected clones were screened by fluorescence-activated call sorter analysis of binding of fluorescent tagged GIP(1-30) (Alexa Fluor 647 dye; Life Technologies), as previously described (25) . The INR1G9-hGIPr cells were cultured at 37°C and 5% CO 2 in Dulbecco modified Eagle medium containing fetal bovine serum (10%), penicillin (100 U/mL), streptomycin (100 mg/mL), and the antibiotic G418 (500 mg/mL) for the selection of the stably transfected cells.
Determination of Binding Affinity
The binding affinity profiles (IC 50 values) of EG1, EG2, EG4, and GIP(1-30) were determined by in vitro GIP receptor autoradiography on cryostat sections of human insulinoma tissue as described previously (20) . The radioligand used was [ 125 I-Tyr 10 ]GIP(1-30) (74,000 GBq [2,000 Ci]/mmol) (Anava) (20, 25) .
Saturation Binding and Internalization Studies
INR1G9-hGIPr cells were seeded at a density of 0.8-1 million cells per well in 6-well plates and incubated with increasing concentrations of either 111/nat In-EG2 or 111/nat In-EG4 (1-100 nM) for saturation binding studies. For internalization studies, approximately 2.5 pmol of the respective radiopeptide were added to the cell medium followed by incubation for 0.5, 1, 2, 4, and 6 h at 37°C, 5% CO 2 . Both procedures are described in detail in the supplemental data.
Animal Model
Female athymic nude mice (age, 4-6 wk; weight, 17-20 g) were purchased from Janvier. For implantation, the cells were harvested by trypsinization and 5 · 10 6 cells in 100 mL of phosphate-buffered saline were inoculated subcutaneously into the right shoulder of the mice. After an average of 2-3 wk, tumors reached 80-100 mg and the animals were used for biodistribution and PET studies. All animal experiments were approved by local authorities and were in compliance with institutional guidelines.
Biodistribution and Renal Uptake Reduction Studies
Ten picomoles/0.03-0.04 MBq of 111 In-EG4 and 68 Ga-EG4 in 100 mL of NaCl 0.9% were injected into the tail vein of INR1G9-hGIPr xenografts. Animals were sacrificed by isoflurane anesthesia at 1, 4, and 24 h after injection in the case of 111 In-EG4 and at 1 and 2 h after injection in the case of 68 Ga-EG4.
Three groups of mice (n 5 4/group) were intravenously administered 100 mL of a modified-fluid-gelatin plasma substitute (Gelofusine; B. Braun) (40 mg/mL), were orally administered 150 mL (10 mmol/kg) of the DPP-4 inhibitor vildagliptin (Galvus [Novartis], 50 mg) dissolved in water, or were given the combination of the two. Gelofusine was administered just before and vildagliptin 1 h before intravenous injection of 10 pmol of the radiotracer. One hour later, the mice were sacrificed. Finally, radioactivity uptake in organs and tumors was calculated as percentage injected activity (%IA)/g. Biodistribution studies were conducted as described in detail in the supplemental data.
Small-Animal PET Studies
The mice were divided into 2 groups (n 5 2/group). The mice of the first group were injected with 100 pmol/0.6-0.8 MBq/100 mL of 68 Ga-EG4, and dynamic imaging was performed with the following acquisition frames: 30 · 10, 10 · 30, 6 · 600, 10 · 60, 10 · 120, and 4 · 300 s, amounting to a total imaging time of 60 min. Twenty-four hours later, the same mice were injected with 100 mL of Gelofusine (40 mg/ mL) and 100 pmol/0.6-0.8 MBq/100 mL of 68 Ga-EG4, and dynamic imaging was performed as described above. Immediately after the end of the dynamic scans, the mice were sacrificed and underwent nephrectomy, and static imaging was performed for 30 min. For the second group, on day 1 the mice were administered 150 mL of vildagliptin by oral gavage (10 mmol/kg). One hour later, intravenous injection of 100 pmol/0.6-0.8 MBq/100 mL of 68 Ga-EG4 followed and dynamic imaging was performed as above. The day after, the same mice 1 h after oral administration of vildagliptin (10 mmol/kg) were injected with 100 mL of Gelofusine (40 mg/mL) and 100 pmol/0.6-0.8 MBq/100 mL of 68 Ga-EG4, followed by dynamic imaging. Blocking experiments were performed as described above, and dynamic scans were obtained for 60 min following the same acquisition frames.
PET images were corrected for 68 Ga decay and reconstructed with filtered backprojection. No correction was applied for attenuation. Images were generated using AMIDE software.
Statistical Analysis
All data are expressed as the mean 6 SD. Prism 5 software (GraphPad Software) was used to determine statistical significance at the 95% confidence level, with a P value of less than 0.05 being considered significantly different.
RESULTS

Peptides and Radiolabeling
The EG1, EG2, and EG4 GIP ligands were custom-synthesized according to the solid-phase peptide synthesis method by Peptide Specialty Laboratories GmbH. The analytic data of the purified conjugates are reported in ½Table 1 Table 1 and in the supplemental material.
The labeling yields for 111 In-conjugates were more than 95% at a specific activity of 7-8 GBq/mmol. The GIP conjugates were labeled with 68 Ga with a labeling yield of more than 98% and a specific activity ranging between 20 and 25 GBq/mmol.
Binding Affinities
Compared with the reference peptide GIP(1-30) (IC 50 , 1.3 6 0.6 nM), EG1, EG2, and EG4 retained high affinity to human GIP receptor (IC 50 : 2.1 6 1.0, 2.5 6 0.8, and 1.5 6 0.7 nM, respectively) (Table 1; Supplemental Fig. 1 ).
Saturation Binding and Internalization Studies
Saturation binding studies were performed at 4°C, to allow binding of the radioconjugates to the receptor but to avoid endocytosis. Both 111/nat In-EG2 and 111/nat In-EG4 exhibited similar affinity for the INR1G9-hGIP, with K d values of 10.6 6 1.6 nM for 111/nat In-EG2 and 8.5 6 1.0 nM for 111/nat In-EG4 ( ½Fig: 1 Fig. 1 ). The B max values were also at the same level for both conjugates (0.7 6 0.04 nM for 111/nat In-EG2 and 1.2 6 0.04 nM for 111/nat In-EG4) and corresponded to approximately 6 · 10 5 receptors per cell (supplemental material).
Both 111 In-labeled GIP ligands were well associated with the INR1G9-hGIPr cells within the 6-h incubation ( ½Fig: 2 Fig. 2 ). Continued exposure of the cells to the radioligands resulted in a gradual increase in the total cell-associated uptake from 30 min to 6 h, which was slightly higher for 111 In-EG4 (19.7% 6 0.8%) than for 111 In-EG2 (14.4% 6 1.4%) at 6 h (P 5 0.0035). The internalized fraction increased with time from 30 min to 6 h, and at 6 h the internalization rate was somewhat higher for 111 In-EG4 (18.3% 6 1.1%) than for 111 In-EG2 (13.5% 6 1.1%) (P 5 0.0054). Almost the entire cell-associated activity was internalized in both cases, supporting their agonist potency. Blocking experiments performed with an excess of GIP (1-30) showed negligible nonspecific binding on the cell surface, whereas less than 0.3% of total added radioactivity was found to be internalized (data not shown), demonstrating the high specificity of the GIP conjugates toward INR1G9-hGIPr cells.
Biodistribution and Renal Uptake Reduction Studies
Both 111 In-EG4 and 68 Ga-EG4 showed fast blood clearance, with 0.04 %IA/g remaining in the blood at 4 h after injection of 111 In-EG4 and 0.03 %IA/g at 2 h after injection of 68 Ga-EG4, resulting in high tumor-to-blood ratios. 111 In-EG4 and 68 Ga-EG4 specifically targeted INR1G9-hGIPr xenografts. The tumor had the highest uptake-10.4 6 2.2 and 17.0 6 4.4 %IA/g, respectively-1 h after injection, and uptake dropped to 2.0 6 0.2 and 1.3 6 0.3 %IA/g 1 h after injection when a 2,000-times excess of GIP(1-30) was preinjected ( ½Table 2   Tables 2 and   ½Table 3 3). Kidney uptake was high and persistent for both 111 In-EG4 and 68 Ga-EG4, reaching values greater than 200 %IA/g. In separated groups of mice (n 5 4/group), 100 mL (40 mg/mL) of Gelofusine or 150 mL (10 mmol/kg) of vildagliptin were administered before the injection of the radiopeptides followed by biodistribution studies at 1 h after injection (Tables 2 and 3 ). The administration of Gelofusine reduced kidney uptake by about 40% (32% for 68 Ga-EG4 [P 5 0.035] and 42% for 111 In-EG4 [P 5 0.034]) without significantly affecting the overall biodistribution profile. Similarly, when vildagliptin was administered, kidney uptake was reduced by a factor of about 2, leading to a tumor-to-kidney ratio of 0.09. The combination of Gelofusine and vildagliptin did not cause a further reduction of kidney uptake (P , 0.05) (Supplemental Table 2 ).
Small-Animal PET Studies
Representative PET images of INR1G9-hGIPr mice on injection of 68 Ga-EG4 were obtained ( ½Fig: 3 Fig. 3 ). Specific tumor uptake was visualized within the 60-min time frame; the initial background uptake of 68 Ga-EG4 in the excretion organs (kidneys) rapidly increased over time. These images well represented the results from the biodistribution studies and particularly the reduction of kidney uptake after administration of Gelofusine or vildagliptin. Furthermore, the nephrectomy allowed better visualization of the abdominal organs that were overlapped by the high kidney uptake. Urinary excretion of the tracer was represented by the high focal activity concentration in the urinary bladder at all time points.
DISCUSSION
Despite almost 30 y of intense research on the development of radiopeptides, only the targeting of NETs has a real impact on patient care (7), because of the high expression of somatostatin and GLP-1 receptors (1). Unfortunately, the lack of somatostatin or GLP-1 receptor in specific NETs, such as insulinomas, demands the identification of a new family of receptors that qualifies for Data are presented as mean ± SD (n 5 4) %IA/g of tissue; blocking studies were performed in presence of 20 nmol of GIP .
successful in vivo targeting of those tumors (20) . In vitro autoradiography studies on tumor tissues from surgical specimens, evaluating the expression of GIP receptor versus somatostatin receptor, have shown that GIP receptor is overexpressed in a given number of samples originating from pancreatic NETs whereas only about 65% of the same samples were found to be positive for somatostatin receptor. Of 24 bronchial NETs, 22 were positive for GIP receptor but only 12 for somatostatin receptor (20) . The fact that most of these tumors retain the GIP receptor even when they lack the somatostatin receptor paves the way for targeting a broader spectrum of NETs. Consequently, the importance of the overexpression of GIP receptor in NETs relies on 2 major advantages: first, the NETs that lack the somatostatin or GLP-1 receptor but retain the GIP receptor may be integrated into the successful peptide receptor targeting method. Furthermore, the simultaneous coexistence of GIP receptor with somatostatin or even GLP-1 receptor in a large number of NETs might argue for multiple receptor targeting using a cocktail of radioligands (8) .
In this frame, we developed and evaluated a new class of radioligands with the potential to be used for the in vivo targeting of GIP receptor-positive tumors. Because the truncated peptide GIP(1-30) activates the GIP receptor as efficiently as the fulllength peptide GIP(1-42) (25) , the GIP(1-30) was chosen as the peptide motif of our study. The peptide was functionalized with the chelator DOTA via 6-Ahx coupled to the side chains of Lys 16 and Lys 30 , respectively, to obtain EG1, EG2, and EG4. In EG4, the Met 14 was substituted with Nle, as a widely used strategy for stabilizing peptides against oxidative damage and allowing easier handling. The GIP conjugates were labeled with 68 Ga and 111 In. Because of its availability from generator systems and the relative ease of labeling chemistry, the positron emitter 68 Ga has gained increasing interest in the field of molecular imaging with PET (28) . On the other hand, 111 In is being used as an important SPECT label and as a surrogate of b emitters such as 90 Y.
The coupling of Ahx-DOTA to Lys side chains of GIP(1-30) independently of the site of modification does not influence the binding affinity of the conjugates toward GIP receptor. The substitution of Met 14 with Nle improved the affinity of EG4 about 1.5-fold compared with EG1. Furthermore, saturation binding studies exhibited high and comparable affinities for both 111/nat In-EG2 and 111/nat In-EG4, with K d values in the low nanomolar range. The further in vitro evaluation showed comparable cellular uptake of the 111 Inlabeled radiopeptides, with 111 In-EG4 exhibiting a somewhat superior profile. In both cases, more than 90% of the total cell-associated activity was internalized into the cancer cells. The almost identical affinity of the DOTA conjugates in comparison to the parent agonist GIP and the efficient receptor-mediated internalization led us to conclude that EGs are agonists (25, 29) . Data are presented as mean ± SD (n 5 4) %IA/g of tissue; blocking studies were performed in presence of 20 nmol of GIP(1-30).
FIGURE 3. PET dynamic imaging of INR1G9-hGIPR tumor-bearing mice on injection of 68 Ga-EG4 at 1 h after injection along with blocking studies. Images clearly visualized tumor and proved the specificity of the radiopeptide; kidney uptake was high. After administration of Gelofusine or vildagliptin, kidney uptake was lower, resulting in better delineation of tumor. After bilateral nephrectomy, 1 h after injection, uptake in abdomen was distinguishable from tumor with weak signal.
